◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound SKIP-FOR-NOW HIGH

Testosterone

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict SKIP-FOR-NOW HIGH

For a healthy 20yo MMA athlete with no documented hypogonadism, exogenous testosterone is unambiguously SKIP. (1) Endogenous T is at lifetime peak in eugonadal 20yo males — typical total T 600-900+ ng/dL with no symptomatic deficit. (2) Exogenous T suppresses an HPG axis that's still consolidating in early adulthood — fertility loss is real and sometimes permanent (Coward J Urol 2013, multiple case reports of persistent oligospermia after a single heavy cycle in young men). (3) Polycythemia risk (Hct >54% → thromboembolic), lipid deterioration, mood lability, and acne are all dose-dependent — at supraphysiologic athletic 'blast' doses the side-effect profile is meaningfully worse than at TRT. (4) TRAVERSE 2023 reassures only for hypogonadal middle-aged/older men at TRT doses — does NOT extrapolate to supraphysiologic use in young eugonadal athletes. (5) For a brain-priority profile, the cognitive return on T in eugonadal young men is essentially zero per the literature. (6) MMA combat sport context adds health/aggression considerations on top — supraphysiologic androgens in late-adolescent PFC development is a soft but real concern. Verdict FLIPS only with documented hypogonadism (total T <300 ng/dL × 2 morning draws + symptoms); even then enclomiphene is the preferred fertility-sparing first-line in young men, NOT exogenous T. Revisit at age 35-40+ if natural decline crosses symptomatic threshold despite optimized lifestyle (sleep, training, BF%, sun, stress, micronutrients).

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, healthy eugonadal (this-archetype)
    SKIP-AT-

    Endogenous T at lifetime peak; HPG suppression risk + fertility + mood/lipid hits + zero documented cognitive benefit at this age. Verdict re-evaluates after June 2026 panel; only flips with documented hypogonadism (T <300 ng/dL × 2 + symptoms), and even then enclomiphene preferred first-line.

  • 30-50, executive maintenance, eugonadal
    CONDITIONAL

    Only with documented low T + symptoms. Enclomiphene preferred first-line for those wanting fertility preservation. T cypionate appropriate for those who've completed family planning and accept lifelong commitment.

  • 35-40+ natural decline (revisit window for the user)
    REVISIT-AT-AGE

    Natural T begins declining ~1%/yr after age 30; clinical hypogonadism prevalence rises substantially by 40s-50s. If symptomatic + T <300-400 ng/dL × 2 — TRT (or enclomiphene first) becomes a STRONG candidate.

  • 50+, mild cognitive decline / sarcopenia / symptomatic low T
    STRONG

    TRAVERSE evidence supports CV safety at TRT doses; T-Trials show real benefit on libido, mood, BMD. Standard of care.

  • Anxiety-prone
    C

    — supra doses can amplify anxiety/irritability; TRT effect variable.

  • High athletic load, tested status (WADA/USADA/employer)
    CATEGORICALLY EXCLUDED

    WADA-banned (S1). Detection: T/E ratio + carbon isotope ratio (CIR/IRMS). Cypionate/enanthate detectable months post-injection. Real career risk.

  • High athletic load, untested status (regional MMA, the user's context)
    OPTIONAL

    with heavy caveats — and SKIP at 20. Some MMA promotions test (state athletic commissions, USADA exit from UFC reshuffled landscape, CSAD picking up); untested regional/local promotions are gray zone. Even if untested, AAS use carries health/fertility/mood/dependence risk — and the brain-priority profile + age 20 makes this SKIP regardless of testing status. Re-evaluate at 30+ after natural ceiling reached.

  • Sleep-disordered
    C

    — can worsen OSA via Hct + soft tissue + central pathway effects.

  • Recovery-focused (post-injury, post-illness)
    S

    low-dose has B-tier evidence in catabolic illness recovery (HIV wasting, severe burns, post-major-surgery) but not relevant to standard gym/sport injuries. BPC-157 is a better-fit recovery tool for the user.

  • Strength/anabolic-focused
    E

    for goal but skip at 20 — endogenous ceiling not yet hit; train + eat + sleep first. Revisit at 30+ if natural ceiling reached. Note: the gap between optimized natural and TRT-dose is meaningful but smaller than people assume; the gap between TRT and supraphysiologic blast is dramatic but with proportional risk.

  • Gender-affirming care (transmasculine)
    STRONG

    Cypionate is standard masculinizing HRT (50-100 mg/wk IM/SubQ titrated to male reference range). Outside scope of the user profile but flagged for completeness.

  • Anti-aging clinic context (40+ healthy "low-normal")
    CONTROVERSIAL

    Endocrine Society sets threshold at 264-300 ng/dL; many anti-aging clinics treat at 400-500 with symptoms. Genuine debate; risk-benefit thinner than for clinical hypogonadism.

▸ Subjective experience (deep)

TRT (100-200 mg/wk) for hypogonadal man: Subtle improvement over weeks. Morning erections improve early (days-weeks), libido return over 2-6 weeks, mood lift slow but real, energy/drive subtle. Body composition shifts over 3-6 months. NOT a 'feel amazing immediately' experience for most — TRT done well is steady, slightly elevated baseline.

Supraphysiologic blast (400-600 mg/wk) in eugonadal man: Distinct phenomenology. Week 1-2: libido + drive surge, training aggression, "I want to dominate" affect. Week 3-6: peak — water retention, full muscle bellies, faster recovery, mood lift bordering on hypomania for some. Sleep often deeper but can become fragmented at high doses. Acne/oily skin emerges in genetically susceptible. Some users describe occasional irritability/aggression spikes ("roid rage" oversimplified — most users report restraint, some experience disinhibition). Body composition response: rapid lean mass + strength + endurance (RBC-mediated) gains — visible in 3-4 weeks, dramatic in 8-10 weeks.

Crash off cycle (without PCT): 2-3 weeks post-last-injection (one ester half-life clearance for cyp/enanthate). Profound fatigue, libido collapse, depressed mood, fat regain, strength loss for 1-6 months. PCT speeds but doesn't guarantee recovery. Some users describe this crash as 'the worst depression I've ever had' — the contrast with peak-on-cycle phenomenology is brutal.

TRT discontinuation (after years on): Same crash pattern but with the added concern that natural HPG recovery may be permanently impaired — original baseline T may not return. This is the underappreciated bargain of TRT — you may not be able to walk back from it.

▸ Tolerance + cycling deep dive
  • AR tolerance: None at the receptor — AR remains responsive indefinitely. "Tolerance" people describe is to subjective lift (the 'feel' plateaus while body comp continues responding). E2 management often resolves perceived tolerance.
  • TRT context: Continuous, no cycling, indefinite (lifelong commitment). Discontinuation = crash + uncertain HPG recovery.
  • Performance / blast context: 10-16 week blast → PCT → minimum 12-16 week off-cycle for HPG recovery attempt. "Blast and cruise" sacrifices natural recovery permanently.
  • Reset (PCT): Wait ester clearance (~3-4 weeks for cyp/enanthate). SERM stack: enclomiphene 12.5-25 mg/d (preferred) OR clomiphene 50→25 mg/d × 4+4 wk OR tamoxifen 20 mg/d × 4-6 wk. hCG 250-500 IU 2-3x/wk during cycle to maintain testicular volume.
  • Recovery panel: 4 weeks post-PCT; full natural recovery often takes 3-12 months, sometimes never in younger users with longer cycles.
▸ Stacking deep dive

Synergistic with (TRT or supraphysiologic context only — irrelevant for SKIP-AT-20)

  • hCG (250-500 IU 2-3x/wk): Maintains testicular volume + intratesticular T for fertility preservation. Standard adjunct in younger TRT patients with fertility goals; speeds PCT recovery in supra context.
  • Enclomiphene (12.5-25 mg/d): First-line alternative to TRT in young hypogonadal men (raises endogenous T via LH/FSH). Sometimes stacked DURING TRT to preserve LH/FSH signaling.
  • Anastrozole (0.25-0.5 mg E3D as needed): Manages E2 at supraphysiologic doses. Rarely needed at TRT doses; over-suppression → joint pain, low libido, lipid issues.
  • Finasteride (1 mg/d) or dutasteride (0.5 mg/d): Hair preservation via 5α-reductase blockade. Caveats: post-finasteride syndrome risk (sexual, cognitive, mood); may attenuate anabolic signaling in some tissues.
  • Fish oil (2-4 g EPA+DHA/day): Partially offsets T-induced lipid panel deterioration. Standard adjunct.
  • Telmisartan or other ARB: BP management if hypertension develops.

Avoid stacking with

  • Methyltestosterone or other oral 17α-alkylated AAS: Hepatotoxic + redundant. Strictly dominated by injectable-only.
  • Trenbolone / nandrolone in young men: Each adds distinct harm (Tren = neuro/CV/sleep nightmare; Nandro = prolactin elevation, 'deca dick', much longer suppression).
  • High-dose stimulants (modafinil + caffeine + ECA stacks): Compound CV strain via additive effects on HR + BP + Hct.
  • Heavy alcohol: Compounds lipid + BP + hepatic load.

Neutral / safe co-administration

  • The user's V4 stack (DHA, magnesium glycinate, creatine, etc.) — no known interaction.
  • Modafinil at standard dose — pharmacokinetically independent.
  • BPC-157, TB-500 — peptides for tissue repair, no interaction.
  • Standard supplements (vitamin D, zinc, B-complex) — neutral or supportive.
▸ Drug interactions deep dive
  • Warfarin: T potentiates warfarin → INR monitoring required, dose adjustment likely.
  • Insulin / oral antidiabetics: T improves insulin sensitivity → may require dose reduction.
  • Corticosteroids: Additive Na/water retention; additive HPA effects.
  • CYP3A4 substrates: T is a substrate; strong inhibitors (ketoconazole, ritonavir) raise T levels modestly. CYP3A4 inducers (rifampin, carbamazepine) modestly reduce.
  • Oxyphenbutazone: Increased oxyphenbutazone levels per FDA label.
  • GnRH agonists/antagonists: Antagonistic — exogenous T blunts utility for prostate cancer or trans-feminine HRT.
▸ Pharmacogenomics
  • AR CAG repeat polymorphism: Shorter CAG repeats (<22) → more sensitive AR → potentially more anabolic + side-effect response at given dose. Longer (>24) → less sensitive. The user's 23andMe (June 2026 results) can hint via raw data analysis.
  • CYP19A1 (aromatase) variants: Affect E2 conversion rate — some men aromatize aggressively at low doses, others resist; relevant to AI need.
  • SRD5A2 (5α-reductase) variants: Affect DHT conversion — relevant to hair, prostate, skin side-effect risk.
  • HSD17B variants: Affect ester cleavage and T/DHT interconversion — minor PK effect.
  • For the user: 23andMe pending June 2026. Genetic profile would inform sensitivity but cannot override SKIP-AT-20 verdict — the issue isn't genetic susceptibility, it's that exogenous T suppresses an HPG axis at lifetime peak with no demonstrated upside at this age.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx (TRT clinic / telehealth) Hone Health, Marek Health, Defy Medical, Maximus, Gameday Men's Health $80-200/mo all-in (incl. labs + visits) High Requires bloodwork showing T <300 ng/dL or below clinic threshold + symptoms. Many telehealth clinics have looser thresholds (treat at 400-500 ng/dL with symptoms). NOT recommended for 20yo without pathology.
US Rx (compounding pharmacy via PCP/endocrinologist) Empower, Olympia, Hallandale, Tailor Made (returning) $30-80/mo for 10mL vial High Cheapest legitimate route. Requires diagnosis. 200 mg/mL standard concentration. Cottonseed or grapeseed oil.
US Rx commercial Pfizer (Depo-Testosterone, brand cyp), Hikma, West-Ward, Perrigo (generics) $150-400/mo via insurance, $300-600 cash High FDA-approved 1957. 100 or 200 mg/mL in cottonseed oil. Insurance covers for diagnosed hypogonadism.
US Rx commercial (oral) Clarus (Jatenzo, T undecanoate) $400-1000/mo retail, varies w/ insurance High First FDA-approved oral T (March 2019). BID dosing. BP elevation black box.
US Rx commercial (SubQ auto-injector) Antares (Xyosted, T enanthate) $200-600/mo High Brand markup; FDA-approved 2018 for SubQ self-injection. Convenience + flatter PK.
US Rx commercial (transdermal) AbbVie (AndroGel), Endo (Testim), Endo (Fortesta), Lilly (Axiron) $150-500/mo High Daily application; transfer risk to children/partners. TRAVERSE used T gel.
US Rx commercial (long-acting IM) Endo (Aveed, T undecanoate IM) $1000-1500 per injection (every 10 wk) High REMS program (pulmonary oil microembolism risk). Office administration only.
Indian / international pharmacy Sun, Cipla, Aristo (cyp/enanthate); various (sustanon) $5-15/vial sourced via India pharma Medium Available OTC-ish in some countries; importing to US is technically illegal at scale (Schedule III) but enforcement against personal-use mail orders is rare. Quality varies.
Gray-market UGL (underground lab) "research lab" / overseas / domestic UGL $40-80 per 10 mL vial Variable Quality roulette: dose accuracy varies (under-dosed or over-concentrated reported); sterility not guaranteed (sterile abscess risk); carrier oil may differ; mail interception possible; legal exposure (Schedule III felony for possession with intent to distribute, simple possession misdemeanor in most states for Rx-pathway diversion). Independent third-party testing (Janoshik, Anabolic Lab) recommended if pursued. NOT recommended for users in this archetype.
▸ Biomarkers to track (deep)

Baseline (the user's June 2026 panel + any future T discussion)

  • Total testosterone (AM 7-10am, fasted, 2 separate draws if low or borderline)
  • Free testosterone (calculated via Vermeulen or direct equilibrium dialysis)
  • SHBG (sex hormone binding globulin — modulates free vs total interpretation)
  • LH, FSH (rules out primary [testicular] vs secondary [pituitary/hypothalamic] hypogonadism)
  • Estradiol — sensitive assay (LC-MS/MS) preferred over standard immunoassay (less interference)
  • Prolactin (rules out prolactinoma if low T + low LH)
  • Hematocrit, hemoglobin (baseline before any erythrocytotic exposure)
  • Lipid panel: HDL, LDL, total cholesterol, triglycerides, ApoB, Lp(a)
  • PSA (baseline even at 20 if T discussed; mandatory if >40)
  • LFTs: AST, ALT, GGT, alk phos, bilirubin
  • HbA1c, fasting insulin, fasting glucose
  • Comprehensive metabolic panel (Na, K, Cl, BUN, Cr, eGFR)
  • Thyroid: TSH, free T4, free T3
  • Body composition: DEXA scan if available (for FFM tracking)
  • Sperm analysis (cryopreservation as harm-reduction insurance pre-cycle if ever pursued)

During use (if ever pursued)

  • 6 weeks post-start: T trough (just before next injection), E2, Hct, lipid panel
  • 3 months: Full panel
  • 6 months: Full panel + PSA
  • Annually: Full panel + DRE if indicated
  • Every 6 months: Hematocrit (donate blood / phlebotomy if >54%)

Post-cycle (if cycled, e.g., supra blast)

  • 4 weeks post-last-injection: T, LH, FSH, E2
  • 12 weeks post: Confirm HPG recovery
  • Sperm analysis if fertility goals (cryopreserve sperm pre-cycle as insurance)
▸ Controversies / open debates Live debate

  1. Cardiovascular safety post-TRAVERSE. TRAVERSE 2023 reassured for MACE non-inferiority in hypogonadal middle-aged/older men at TRT doses. BUT increased atrial fibrillation, PE, AKI signals remain. The pre-TRAVERSE FDA black box warning (2014) was based on weaker observational data; TRAVERSE walked it back at MACE level but not at arrhythmia/thromboembolic level. Honest read: TRT in clinically hypogonadal men is CV-safe in the studied population; supraphysiologic dosing in young eugonadal athletes has no comparable data.

  2. Diagnostic threshold for hypogonadism. Endocrine Society 2018 (Bhasin JCEM 2018, PMID 29562364) sets 264 ng/dL based on harmonized reference range; AUA 2018 (updated 2024) uses 300 ng/dL × 2 + symptoms. Many telehealth clinics treat at 400-500 ng/dL with symptoms — beyond guideline support. Genuine debate; some men have low SHBG and adequate free T despite low total. Free T or bioavailable T may be better criterion than total T alone.

  3. TRT vs enclomiphene first-line in young hypogonadal men. Younger men with fertility goals should try enclomiphene first (raises endogenous T via LH/FSH stimulation, preserves spermatogenesis) before exogenous T (which suppresses HPG axis and may permanently impair fertility). Many TRT clinics skip this step — bias toward T cypionate due to clinical familiarity + revenue model.

  4. Fertility recovery post-cycle. Some men recover fully post-PCT; others remain subfertile/infertile. Risk factors for non-recovery: longer cycles, higher doses, age >35, baseline low FSH. Younger users at 20 are NOT protected — multiple case reports of permanent oligospermia after a single heavy cycle (Coward J Urol 2013, PMID 23764075). Sperm cryopreservation pre-cycle is cheap harm reduction.

  5. Bone density gain vs fracture reduction. T-Trials Bone Trial (Snyder JAMA Int Med 2017, PMID 28241231) showed +7.5% spine vBMD on TRT. TRAVERSE Bone Substudy (Snyder NEJM 2024, PMID 38231621) showed numerically MORE fractures in T arm despite BMD gains — surprised the field. Possible mechanisms: increased risk-taking, altered fall dynamics, micro-architecture vs density disconnect. Implication: BMD improvement on TRT does NOT automatically translate to clinical fracture reduction.

  6. SubQ vs IM. SubQ produces flatter PK with reduced Hct rise and equivalent clinical effect (Spratt JCEM 2017). IM remains standard; SubQ increasingly preferred in modern TRT. Patient preference + insulin syringe self-administration + fewer peak-trough symptoms → SubQ wins on most axes.

  7. Brain development at 20. Prefrontal cortex matures into mid-20s; supraphysiologic androgens during this window may affect impulsivity-related neural development (animal data + theoretical concern; limited direct human evidence). Soft concern but worth flagging for users in this archetype-archetype users.

  8. Combat sport mental-health context. Aggression literature contested — meta-analyses show modest increase in irritability/aggression at supra doses, large individual variance. Combat sport context plus supraphysiologic androgen plus age 20 is a combination worth flagging conservatively.

  9. MMA testing landscape circa 2026. USADA exit from UFC (2023-2024) reshuffled the detection landscape; CSAD (Combat Sports Anti-Doping) and state athletic commissions are now primary testing bodies. Detection windows for cypionate metabolites: months. Real risk for any tested fight; gray zone in untested regional promotions.

  10. 'Bioidentical' framing. True at the molecule level (T is T) but misleading — exogenous T suppresses endogenous regardless of ester or molecule shape. The "natural" branding of TRT marketing oversells safety.

▸ Verdict change log
  • 2026-05-10 — Initial verdict: SKIP-AT-20 (HIGH confidence). Rationale: For a healthy 20yo MMA athlete with no documented hypogonadism, exogenous testosterone is unambiguously SKIP. Endogenous T at lifetime peak; HPG suppression with documented fertility/mood/lipid risks; no demonstrated benefit in eugonadal young men. Re-evaluate post June 2026 bloodwork; only flips to "conditional TRT" with documented hypogonadism (T <300 ng/dL × 2 + symptoms). Even then, enclomiphene preferred first-line for fertility preservation. Revisit window: age 35-40+ if natural T crosses symptomatic threshold despite optimized lifestyle.
▸ Open questions / gaps Open
  • The user's June 2026 baseline T, LH, FSH, SHBG — until in hand, this verdict is partially blind. If unexpectedly low T + low LH/FSH at 20 (secondary hypogonadism pattern), enclomiphene is strongly indicated before any T consideration.
  • AR CAG repeat from 23andMe (raw data analysis post-June 2026) — would inform sensitivity if T ever discussed.
  • Subconcussive impact effect on HPG axis: emerging literature suggests pituitary microtrauma in contact athletes may produce secondary hypogonadism. Worth checking if June panel shows unexpected low T + low LH/FSH pattern in the user.
  • Family history of hypogonadism, fertility issues, testicular pathology, prostate cancer — TBD per profile.
  • MMA promotion testing landscape circa 2026 — varies by promotion and state commission.
  • Long-term consequences of TRAVERSE atrial fibrillation signal — additional follow-up data forthcoming.
▸ Cross-references

References

Lincoff AM et al. 2023 — Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE) (NEJM)

pubmed.ncbi.nlm.nih.gov · 2023

PMID 37326322; foundational CV safety trial

View Study

Snyder PJ et al. 2016 — Effects of Testosterone Treatment in Older Men (T-Trials main results) (NEJM)

pubmed.ncbi.nlm.nih.gov · 2016

PMID 26886521

View Study

Snyder PJ et al. 2017 — Effect of Testosterone Treatment on Volumetric Bone Density and Strength (T-Trials Bone Trial) (JAMA Internal Medicine)

pubmed.ncbi.nlm.nih.gov · 2017

PMID 28241231

View Study

Snyder PJ et al. 2024 — Testosterone Treatment and Fractures in Men with Hypogonadism (TRAVERSE Bone Substudy) (NEJM)

pubmed.ncbi.nlm.nih.gov · 2024

PMID 38231621

View Study

Bhasin S et al. 1996 — Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal Men (NEJM)

pubmed.ncbi.nlm.nih.gov · 1996

PMID 8637535

View Study

Mulhall JP et al. 2018 (updated 2024) — AUA Testosterone Deficiency Guideline

auanet.org · 2018
View Source

Depo-Testosterone (testosterone cypionate) — FDA Label

accessdata.fda.gov
View Source

Jatenzo (testosterone undecanoate, oral) — FDA Label

accessdata.fda.gov
View Source

Xyosted (testosterone enanthate SubQ) — FDA Label

accessdata.fda.gov
View Source

WADA Prohibited List 2026

wada-ama.org · 2026
View Source

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…